An environmentally friendly and sensitive method for determination of blockers and agonists was described in this paper. The method is based on a homemade sol-gel solid-phase microextraction (SPME) coating with simultaneous on-fiber derivatization and subsequent gas chromatography mass spectrometry (GC/MS) analysis. The influences of the main factors on the type and thickness of the homemade fiber coatings, conditions of the derivatization, extraction and desorption of SPME were investigated in detail. The proposed procedure showed limits of detection lower than 0.2 ng mL(-1). The linearity was in the 0.5-150 ng mL(-1) for clenbuterol and 1.0-100 ng mL(-1) for metoprolol and propranolol. The variation in measurements (repeatability) was below 8.7% (n=6) and the degree of difference between (reproducibility) was below 11.4% (n=3). In the application, spiked human saliva samples and real human saliva samples were analyzed, it was found that saliva would affect the detection of propranolol when it was a very low content. The established method can be feasible in practical application and helpful for agonists and blockers preliminary screening during the competition.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.talanta.2014.07.064DOI Listing

Publication Analysis

Top Keywords

determination blockers
8
blockers agonists
8
on-fiber derivatization
8
solid-phase microextraction
8
human saliva
8
saliva samples
8
simultaneous determination
4
agonists on-fiber
4
derivatization self-made
4
self-made solid-phase
4

Similar Publications

Background Introduction: Vestibular schwannoma (VS) tumors typically present with sensorineural hearing loss (SNHL). Losartan has recently demonstrated prevention of tumor-associated SNHL in a mouse model of VS through suppression of inflammatory and pro-fibrotic factors, and the current study investigates this association in humans.

Methods: This is a retrospective study of patients with unilateral VS and hypertension followed with sequential audiometry at a tertiary referral hospital from January 1994 to June 2023.

View Article and Find Full Text PDF

Aims: The purpose of this systematic review was to assess the safety and effectiveness of beta antagonists for improving clinical care in burn patients, compared to placebo.

Methods: Articles from randomized-controlled trials were identified by a literature search on PubMed and Cochrane. We included relevant trials involving patients with burn.

View Article and Find Full Text PDF

Aims: Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.

Methods And Results: This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status. The primary endpoint was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8.

View Article and Find Full Text PDF

Background: Transient receptor potential cation channel subfamily V member 2 (TRPV2) functions as a stretch-sensitive calcium channel, with overexpression in the sarcolemma of skeletal and cardiac myocytes leading to detrimental calcium influx and triggering muscle degeneration. In our previous pilot study, we showed that tranilast, a TRPV2 inhibitor, reduced brain natriuretic peptide levels in two patients with muscular dystrophy and advanced heart failure. Building on this, we performed a single-arm, open-label, multicenter study herein to evaluate the safety and efficacy of tranilast in the treatment of advanced heart failure in patients with muscular dystrophy.

View Article and Find Full Text PDF

Angiotensin type 1 and type 2 receptors-induced mitochondrial dysfunction promotes ferroptosis in cardiomyocytes.

J Hum Hypertens

January 2025

Geriatrics Center & National Clinical Research Center for Aging and Medicine, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, China.

Previous studies suggest that ferroptosis is involved in cardiovascular diseases. The aim of the present study is to investigate the causal relationship between angiotensin II type 1 and type 2 receptors (ATR) activities and mitochondrial dysfunction in induction of cardiomyocyte ferroptosis. Human AC16 cardiomyocytes were first pre-treated with an ATR blockers, before stimulated with angiotensin II (Ang II) for 24 h.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!